Clinical trials: Constipation, Opioid-Induced
Chronic Pain, Opioid Induced Constipation
Naloxone SR Capsules in Patients With Opioid Induced Constipation
For many patients taking opioids for pain relief one of the most distressing side effects is constipation. Naloxone is effective in the reversal of the effects of opioids and is used following opioid overdose.
- Trial name
- NCT00984334
- Testing
- Naloxone SR 5 mg capsules, Naloxone SR 10 mg capsules, Naloxone SR 20mg capsules
- Where
- 8 sites in Germany, United Kingdom
- Volunteers
- 40 people
- Sponsor
- S.L.A. Pharma AG
Chronic Severe Pain
A Non-interventional, Observational Study for Quality of Life (Overall Health Assessment) in Patients With Chronic Severe Pain During Targinact® Treatment
This non-interventional, observational study evaluates the efficacy of Targinact with regard to quality of life in daily clinical practice in Belgium compared to the previous analgesic treatment.
- Trial name
- NCT01710917
- Testing
- Targinact® (oxycodon/naloxon)
- Where
- Belgium
- Volunteers
- 1,800 people
- Sponsor
- Mundipharma CVA
Severe Pain
A Non-interventional, Observational Study for Targinact® Treatment in Patients With Severe Pain.
This non-interventional, observational study evaluates the efficacy of Targinact with regard to pain relief in daily clinical practice in Belgium compared to the previous analgesic treatment.
- Trial name
- NCT01983137
- Testing
- Targinact® (oxycodone/naloxone)
- Where
- Belgium
- Volunteers
- 1,338 people
- Sponsor
- Mundipharma CVA
Opioid-induced Constipation
ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
The purpose of this study is to evaluate the safety, tolerability and efficacy of ALKS 37 when administered daily for 4 weeks to adults with Opioid-induced Constipation (OIC).
- Trial name
- NCT01382797
- Testing
- ALKS 37
- Where
- 20 sites in United States
- Volunteers
- 157 people
- Sponsor
- Alkermes, Inc.
Opioid-induced Constipation
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
This study will evaluate the safety and efficacy of Tegaserod in opioid-induced constipation (OIC) in patients with non-cancer pain.
- Trial name
- NCT00399659
- Testing
- Tegaserod
- Where
- 57 sites in United States
- Volunteers
- 360 people
- Sponsor
- Novartis
Constipation
Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain
This study will evaluate the efficacy and safety of tegaserod in opioid-induced constipation in patients with non-cancer pain.
- Trial name
- NCT00365820
- Testing
- Tegaserod
- Where
- 59 sites in United States
- Volunteers
- 670 people
- Sponsor
- Novartis
Opioid-induced Constipation
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
This study will evaluate the safety and efficacy of Tegaserod in opioid-induced constipation in patients with non-cancer pain. Patients who enter this study PRIOR to the core study (CHTF919N2201) interim analysis receive the…
- Trial name
- NCT00414024
- Testing
- Tegaserod
- Where
- 6 sites in United States, China and 4 more
- Volunteers
- 11 people
- Sponsor
- Novartis
Opioid-induced Constipation
ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)
The purpose of this study is to assess the safety and tolerability of RDC-1036 (ALKS 37) in adults with opioid-induced constipation (OIC) following repeat dose administration
- Trial name
- NCT01100151
- Testing
- RDC-1036 (ALKS 37)
- Where
- 11 sites in United States
- Volunteers
- 60 people
- Sponsor
- Alkermes, Inc.
Opioid-induced Constipation
Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit
The purpose of this study is to determine if there will be a significantly higher incidence of a bowel movement with methylnaltrexone vs.
- Trial name
- MOVE-IT (NCT01050595)
- Testing
- Methylnaltrexone Bromide
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- St. John Health System, Michigan